The experimental research on antitumor immune response of tumor-bearing mice by S-180 tumor cells and BCG vaccines

The Active Specifie Immunotherapy of BaIb/c mice which bearing 1 × 10⁵ Sarcoma 180 cells after treatment with irration syngeneic tumor cells and BCG vaccines was studied. The rasults show that the Active Specific Immunotherapy rignificantly lncreased the delayed-type cutaneous hypersensitivity (DCH) responses to syngeneic tumor cells and BCG in 18 of 20 mice (90%). Compared with control group or alone treatment group (syngeneic tumor cells or BCG), the survival period of tumor-bearing mice which combined treatment lasted significanting (P<0.05). Four mice among these treated mice have sutwved for 34, 38, 59, 66 days respectively, showing the significant antitumor response to the treatment. The treatment is also effective in inhibition of tumor's dissmination to lung. The studies demonstrate that the Immune method established by Hanna may enhanced antitumor immune response of tumor-bearing mice (1 × 10⁵). The goal was to determine whether tumorbearing mice treated with vaccines made of syngenteic tumor cells combined with BCG as adjuvant would have an increased reaction to syngeneic tumor cells as measured by DCH responses.